Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 958-967

  Petrylak, Daniel P ^a   Macarthur, Robert B ^a   O'Connor, John ^a   Shelton, Gary ^a   Judge, Timothy ^a   Balog, Joshua ^a   Pfaff, Charles ^a   Bagiella, Emilia ^a   Heitjan, Daniel ^a   Fine, Robert ^a   Zuech, Nancy ^a   Sawczuk, Ihor ^a   Benson, Mitchell ^a   Olsson, Carl A ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; NARCOTIC ANALGESIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0032976896     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.958     Document Type: Article

References (35)

1. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 371:1098-1109, 1993
2. Eisenberger MA, Abrams JS: Chemotherapy for prostatic carcinoma. Semin Urol 6:303-310, 1988
3. Perry CA, McTavish D: Estramustine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7:149-174, 1995
4. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581, 1993
5. Stearns ME, Wang M, Tew K, et al: Estramustine binds a MAP-1 like to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU-145 cells. J Cell Biol 107:2647-2656, 1988
6. Speicher LA, Barone L, Chipman E: P-glycoprotein binding and modulation of the multidrug resistance phenotype by estramustine. J Natl Cancer Inst 86:688-694, 1994
7. Yang CP, Shen HJ, Horowitz SB: Modulation of the function of p-glycoprotein by estramustine. J Natl Cancer Inst 86:3723-3724, 1994
8. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993
9. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992
10. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point in hormone refractory prostate cancer. J Urol 147:931-934, 1992
11. Amato RJ, Ellenhorst J, Bui C, et al: Estramustine and vinblastine for patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 2:168-172, 1995
12. Hudes GH, Greenberg R, Krigel R, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
13. Hudes GR, Nathan F, Khater C, et al: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-3163, 1997
14. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
15. Riou JF, Petitgenet, Combeau C, et al: Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35:385, 1994 (abstr 2292)
16. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reverseability, ligand stoichiometry, and competition. Biochemistry 32:2747-2755, 1993
17. Vergniols JC, Bruno R, Montay G, et al: Determination of taxotere in human plasma by a semiautomated HPLC method. J Chromatog 582:273-278, 1992
18. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:487-491, 1958
19. Bruno R, Hille D, Riva A, et al: Population pharmackinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
20. Piccart MJ, Klijn J, Paridaens R, et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer investigational drug branch for breast cancer. J Clin Oncol 15:3149-3155, 1997
21. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
22. Hudes G, Roth BG, Loehrer P, et al: Phase III trial of vinblastine versus vinblastine plus estramustine phosphate for metastatic hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 16:316A, 1997 (abstr 1127)
23. Gunnarsson PO, Davidsson T, Andersson B, et al: Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol 38:189-193, 1990
24. Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997
25. Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced hormone-refractory prostate carcinoma phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460, 1993
26. Tannock IF, Osoboa D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone vs prednisone alone for symptomatic hormone-refractory prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1796-1764, 1996
27. Kelly WK, Curley T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patient with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995
28. Dawson NA, Cooper M, Figg W, et al: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:435-461, 1995
29. Storlie JA, Buckner JC, Wiseman GA, et al: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate cancer. Cancer 76:96-100, 1995
30. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:5590-5597, 1989
31. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP56976 NCSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
32. Royer I, Monsarrat B, Sonnier M, Wright M, Crestiel T: Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58-65, 1996
33. Gunnarsson P, Forshell G: Clinical pharmacokinetics of estramustine phosphate. Urology 23:22-27, 1984 (suppl 6)
34. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of taxotere. Cancer Surv 17:305-313, 1993 (review)
35. Kantoff PW, Conoway M, Winer E, et al: Hydrocortisone (HC) with or without mitoxantrone (M) in patients (pts) with hormone refractory prostate cancer (HPRC): Preliminary results from a prospective randomized Cancer and Leukemia Group B Study (9182) comparing chemotherapy to best supportive care. J Clin Oncol 14:1748, 1996 (abstr 2013)